# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2141-2150 of 2220 results.
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Completed
Last Changed: Jan 27, 2020
First Received: Jan 28, 2008
Disease(s): Leukemia, Lymphoma
Intervention(s): Rituximab, Cyclophosphamide, Lenalidomide, Pentostatin
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Status: Completed
Last Changed: Oct 09, 2019
First Received: Dec 05, 2014
Disease(s): Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
Intervention(s): Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Completed
Last Changed: Sep 28, 2020
First Received: Apr 02, 2015
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell
Intervention(s): CC-122, CC-122, Ibrutinib, CC-122, Obinutuzumab
Locations: University of California San Diego, La Jolla, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Weill Cornell Medical College Dr. Feldman's Office, New York, New York, United States
Ohio State University Medical CenterJames Cancer Hospital, Columbus, Ohio, United States
... and 20 other locations.
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom
Status: Completed
Last Changed: Feb 15, 2016
First Received: Mar 28, 2008
Disease(s): Non-Hodgkin's Lymphoma
Intervention(s): Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)
Locations: H.U. Central de Asturias, Oviedo, Oviedo, Asturias, Spain
H.Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Clínica Universitaria de Navarra, Pamplona, Navarra, Spain
Hospital Universitario de Alicante, Alicante, Spain
H. de la Santa Creu i Sant Pau, Barcelona, Spain
... and 14 other locations.
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Status: Completed
Last Changed: Jul 02, 2017
First Received: Apr 09, 2003
Disease(s): B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Waldenström Macroglobulinemia
Intervention(s): alvocidib
Locations: Ohio State University Medical Center, Columbus, Ohio, United States
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Status: Available
Last Changed: Sep 15, 2020
First Received: Nov 14, 2019
Disease(s): Relapse/Refractory Mantle Cell Lymphoma
Intervention(s): Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
Locations: Stanford Cancer Institute, Stanford, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Cleveland Clinic, Cleveland, Ohio, United States
... and 4 other locations.
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Status: Unknown status
Last Changed: Oct 06, 2006
First Received: Oct 06, 2006
Disease(s): Lymphoma, High-Grade
Intervention(s): Bendamustine, Rituximab
Locations: University of Magdeburg, departement of Hematology and Oncology, Magdeburg, Germany
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Status: Completed
Last Changed: May 12, 2011
First Received: Jan 27, 2003
Disease(s): Leukemia, Lymphoma
Intervention(s): rituximab, cyclophosphamide, pentostatin
Locations: Hoag Cancer Center at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
Status: Completed
Last Changed: Aug 07, 2020
First Received: Mar 26, 2018
Disease(s): Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Intervention(s): Ibrutinib
Locations: Apollo Hospitals International Limited, Ahmedabad, India
Healthcare Global (HCG) Hospital, Bangalore, India
Fortis Memorial Research Institute, Gurgaon, India
Basavatarakam Indo-American Hospital, Hyderabad, India
Bhagwan Mahaveer Hospital & Research Centre, Jaipur, India
... and 4 other locations.
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
Status: Recruiting
Last Changed: Nov 27, 2019
First Received: Apr 12, 2017
Disease(s): B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Hematopoietic/Lymphoid Cancer, Refractory Chronic Lymphocytic Leukemia
Intervention(s): anti-CD19 CAR-T, Fludarabine, Cyclophosphamide
Locations: The First Affilicated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China